Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free NDRA Stock Alerts

ENDRA Life Sciences (NDRA) Competitors

ENDRA Life Sciences logo
$5.60 +0.14 (+2.56%)
Closing price 05/22/2026 03:59 PM Eastern
Extended Trading
$5.52 -0.08 (-1.43%)
As of 05/22/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NDRA vs. AGPU, TMDIF, FEMY, RVP, and ZJYL

Should you buy ENDRA Life Sciences stock or one of its competitors? MarketBeat compares ENDRA Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ENDRA Life Sciences include Predictive Oncology (AGPU), Titan Medical (TMDIF), Femasys (FEMY), Retractable Technologies (RVP), and Jin Medical International (ZJYL). These companies are all part of the "medical equipment" industry.

How does ENDRA Life Sciences compare to Predictive Oncology?

Predictive Oncology (NASDAQ:AGPU) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

ENDRA Life Sciences has lower revenue, but higher earnings than Predictive Oncology. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Predictive Oncology$120K462.80-$233.10M-$8.18N/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ENDRA Life Sciences has a consensus price target of $30.00, suggesting a potential upside of 435.71%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Predictive Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Predictive Oncology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Predictive Oncology had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 1 mentions for Predictive Oncology and 0 mentions for ENDRA Life Sciences. Predictive Oncology's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Predictive Oncology Neutral
ENDRA Life Sciences Neutral

ENDRA Life Sciences has a net margin of 0.00% compared to Predictive Oncology's net margin of -470,383.31%. ENDRA Life Sciences' return on equity of -433.64% beat Predictive Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Predictive Oncology-470,383.31% -7,363.67% -626.32%
ENDRA Life Sciences N/A -433.64%-204.58%

Predictive Oncology has a beta of 3.45, meaning that its stock price is 245% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.11, meaning that its stock price is 111% less volatile than the broader market.

Summary

ENDRA Life Sciences beats Predictive Oncology on 9 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Titan Medical?

ENDRA Life Sciences (NASDAQ:NDRA) and Titan Medical (NASDAQ:TMDIF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

ENDRA Life Sciences has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

In the previous week, ENDRA Life Sciences' average media sentiment score of 0.00 equaled Titan Medical'saverage media sentiment score.

Company Overall Sentiment
ENDRA Life Sciences Neutral
Titan Medical Neutral

Titan Medical has higher revenue and earnings than ENDRA Life Sciences. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Titan Medical$17.63M1.32$6.95M$0.054.08

Titan Medical's return on equity of -82.31% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Titan Medical N/A -82.31%-51.47%

ENDRA Life Sciences presently has a consensus target price of $30.00, suggesting a potential upside of 435.71%. Given ENDRA Life Sciences' stronger consensus rating and higher probable upside, research analysts plainly believe ENDRA Life Sciences is more favorable than Titan Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Titan Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Titan Medical beats ENDRA Life Sciences on 7 of the 12 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Femasys?

ENDRA Life Sciences (NASDAQ:NDRA) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

1.2% of ENDRA Life Sciences shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Comparatively, 7.6% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ENDRA Life Sciences has higher earnings, but lower revenue than Femasys. Femasys is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A
Femasys$2.29M11.55-$18.63M-$0.27N/A

In the previous week, Femasys had 2 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 2 mentions for Femasys and 0 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 0.00 equaled Femasys'average media sentiment score.

Company Overall Sentiment
ENDRA Life Sciences Neutral
Femasys Neutral

ENDRA Life Sciences has a beta of -0.11, indicating that its share price is 111% less volatile than the broader market. Comparatively, Femasys has a beta of -2.26, indicating that its share price is 326% less volatile than the broader market.

ENDRA Life Sciences has a net margin of 0.00% compared to Femasys' net margin of -521.97%. Femasys' return on equity of -258.08% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
ENDRA Life SciencesN/A -433.64% -204.58%
Femasys -521.97%-258.08%-73.72%

ENDRA Life Sciences currently has a consensus price target of $30.00, indicating a potential upside of 435.71%. Femasys has a consensus price target of $5.33, indicating a potential upside of 1,117.66%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than ENDRA Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Femasys
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Femasys beats ENDRA Life Sciences on 9 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Retractable Technologies?

Retractable Technologies (NYSE:RVP) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

ENDRA Life Sciences has a consensus target price of $30.00, suggesting a potential upside of 435.71%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Retractable Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Retractable Technologies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

7.6% of Retractable Technologies shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 59.5% of Retractable Technologies shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Retractable Technologies has higher revenue and earnings than ENDRA Life Sciences. Retractable Technologies is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Retractable Technologies$37.15M0.57-$7.01M-$0.21N/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

Retractable Technologies has a beta of 1.25, indicating that its stock price is 25% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.11, indicating that its stock price is 111% less volatile than the broader market.

In the previous week, ENDRA Life Sciences' average media sentiment score of 0.00 beat Retractable Technologies' score of -1.00 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company Overall Sentiment
Retractable Technologies Negative
ENDRA Life Sciences Neutral

ENDRA Life Sciences has a net margin of 0.00% compared to Retractable Technologies' net margin of -41.11%. Retractable Technologies' return on equity of -17.15% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Retractable Technologies-41.11% -17.15% -9.33%
ENDRA Life Sciences N/A -433.64%-204.58%

Summary

Retractable Technologies beats ENDRA Life Sciences on 8 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Jin Medical International?

Jin Medical International (NASDAQ:ZJYL) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

In the previous week, Jin Medical International's average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company Overall Sentiment
Jin Medical International Neutral
ENDRA Life Sciences Neutral

Jin Medical International has a beta of 7.52, suggesting that its share price is 652% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market.

Jin Medical International's return on equity of 0.00% beat ENDRA Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Jin Medical InternationalN/A N/A N/A
ENDRA Life Sciences N/A -433.64%-204.58%

ENDRA Life Sciences has a consensus target price of $30.00, indicating a potential upside of 435.71%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Jin Medical International.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jin Medical International
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ENDRA Life Sciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Jin Medical International has higher revenue and earnings than ENDRA Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jin Medical International$20.69M0.90$1.19MN/AN/A
ENDRA Life SciencesN/AN/A-$7.03M-$8.15N/A

1.2% of ENDRA Life Sciences shares are owned by institutional investors. 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Jin Medical International and ENDRA Life Sciences tied by winning 5 of the 10 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for NDRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NDRA vs. The Competition

Export
MetricENDRA Life SciencesMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$6.93M$7.10B$6.46B$12.34B
Dividend YieldN/A1.68%2.76%5.28%
P/E Ratio-0.6947.4521.0025.66
Price / SalesN/A73.72562.1886.31
Price / CashN/A24.9143.4956.67
Price / Book3.976.5310.417.14
Net Income-$7.03M$158.81M$3.57B$335.98M
7 Day Performance0.18%3.61%6.40%4.11%
1 Month Performance12.68%0.74%3.54%2.52%
1 Year Performance80.06%3.17%34.14%35.04%

ENDRA Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NDRA
ENDRA Life Sciences
2.3228 of 5 stars		$5.60
+2.6%		$30.00
+435.7%		+80.1%$6.93MN/AN/A20
AGPU
Predictive Oncology
0.4549 of 5 stars		$4.76
+1.7%		N/AN/A$25.92M$120KN/A30
TMDIF
Titan Medical
N/A$0.20
-10.3%		N/A-26.0%$22.92M$17.63MN/A50
FEMY
Femasys
2.1398 of 5 stars		$0.36
-1.2%		$5.33
+1,387.3%		-57.9%$21.91M$2.29MN/A30
RVP
Retractable Technologies
N/A$0.68
+1.6%		N/A+9.9%$20.39M$38.27MN/A240

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel